Chemotherapy News and Research

Latest Chemotherapy News and Research

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.

3 Apr 2010

RPCI studies potential of CellSearch test for monitoring treatment results in metastatic gallbladder patients

Renuka Iyer, MD, of the Department of Medicine, and Dan Iancu, MD, of the Department of Pathology and Laboratory Medicine at Roswell Park Cancer Institute (RPCI) are studying how a new test called CellSearch could be used with standard radiographic methods to monitor treatment results in patients with locally advanced or metastatic gallbladder or biliary duct cancers. The goal of the study is to see if CellSearch could predict patient response to therapy earlier than traditional measures.

2 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

Investment report on ADVENTRX Pharmaceuticals

BeaconEquity.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

EvoLife Laboratories introduces cancer care products in USA

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, announced the launch of its products in USA.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Insight into scorpion venom may help understand diseases like pancreatitis

A Brazilian scorpion has provided researchers at North Carolina State University and East Carolina University insight into venom's effects on the ability of certain cells to release critical components. The findings may prove useful in understanding diseases like pancreatitis or in targeted drug delivery.

30 Mar 2010

Kylie Minogue supports breast cancer initiative

Australian singer Kylie Minogue is part of this year’s Fashion Targets Breast Cancer campaign. Kylie is a cancer survivor who was diagnosed with the disease in May 2005. She had to cancel her Showgirl world tour’s Australian leg because of that.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

Health Robotics launches global Beta installation of 3 i.v.SOFT Workflow Engine automation modules

Health Robotics today announced the successful global launch of the Beta Installation kick-off for its 3 latest i.v.SOFT Workflow Engine software automation modules [Assist, Label+ and Profile] in Nice [France], the 2010 venue for the European Association of Hospital Pharmacists. i.v.SOFT helps Pharmacy Technicians, I.V. Room Supervisors, and Pharmacy Directors to compound and manage the safe and efficient manual production of IV Admixtures according to hospital-defined sterile compounding guidelines, and to help bring the pharmacies into compliance with USP 797 regulations in the United States and GMP guidelines elsewhere.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Pacemaker in stomach can help treat severe stomach disorders and chronic vomiting

People with severe stomach disorders can sometimes suffer from chronic vomiting. This symptom can be treated with electrical impulses from a pacemaker in the stomach. A new method enables patients who could benefit from this treatment to be identified, and electrical stimulation leads to reduced nausea and fewer days in hospital, shows a study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

29 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

RPCI studies potential of CellSearch test for monitoring treatment results in metastatic gallbladder patients

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Investment report on ADVENTRX Pharmaceuticals

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

New medicines to fight diseases of particular concern to African Americans

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

DSMB for DIGNITY trial recommends Celsion continue enrollment

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

EvoLife Laboratories introduces cancer care products in USA

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Insight into scorpion venom may help understand diseases like pancreatitis

Kylie Minogue supports breast cancer initiative

Research challenges current thinking about TB bacterium

Health Robotics launches global Beta installation of 3 i.v.SOFT Workflow Engine automation modules

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pacemaker in stomach can help treat severe stomach disorders and chronic vomiting

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in